Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report
Frontiers in Pharmacology · 20.11.2026 · 17
DOI: 10.3389/fphar.2026.2006744 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.11.2026. Verfasst von Xue Han und 5 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Therapeutic options for metallo-β-lactamase (MBL)-producing carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in neonates are extremely limited, particularly after the emergence of polymyxin resistance. Evidence supporting ceftazidime-avibactam (CAZ-AVI) plus aztreonam (ATM) in extremely preterm infants remains scarce. Case Presentation A male infant born at 27 +6 weeks’ gestation with a birth weight of 1,200 g developed perforated necrotizing enterocolitis requiring bowel resection and enterostomy. During hospitalization, he experienced three episodes of NDM-producing CRKP bloodstream infection. The polymyxin B MIC increased from 1 μg/mL in the initial isolate to 4 μg/mL in the third isolate, with the latter result confirmed by repeat broth microdilution testing. Severe intestinal failure-associated liver disease (IFALD) also developed, with a peak direct bilirubin concentration of 426 μmol/L. Synergy testing demonstrated restored activity of CAZ-AVI plus ATM despite resistance to each agent alone. The infant received both CAZ-AVI (50 mg/kg every 8 h) and ATM (30 mg/kg every 8 h) for approximately 7 weeks. Management also included high dose pure fish oil-lipid emulsions (FO-ILE) therapy, anticoagulation guided by thrombotic biomarkers, individualized nutritional support, and delayed intestinal reconstruction.
Results
Blood cultures and mNGS became negative following combination therapy. After restoration of intestinal continuity, inflammatory markers normalized, cholestasis resolved completely, and full enteral autonomy was achieved. No treatment-related adverse events or renal dysfunction occurred. At 15 months of age (12 months corrected age), growth and neurodevelopment were satisfactory.
Conclusion
Successful treatment required not only synergistic antimicrobial therapy but also early initiation of oral or enteral feeding through intestinal reconstruction and FO-ILE therapy. This case highlights the importance of integrating antimicrobial, surgical, nutritional strategies in extremely preterm infants with multidrug-resistant infections complicated by intestinal failure and IFALD.
Zitieren
APA
Han, X., Huang, L., Jiang, X., Zhang, M., Zhou, W., & Zhang, L. (2026). Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2006744
Vancouver
Han X, Huang L, Jiang X, Zhang M, Zhou W, Zhang L. Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2006744
BibTeX
@article{Han2026,
author = {Han, Xue and Huang, Liang and Jiang, Xiaoping and Zhang, Min and Zhou, Wei and Zhang, Li},
title = {Ceftazidime–avibactam plus aztreonam for recurrent NDM-Producing Klebsiella pneumoniae infection following polymyxin B exposure in an extremely preterm infant: a case report},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2006744}
}
EUVIMED